@article{oai:shiga-med.repo.nii.ac.jp:00004344,
 author = {小出, 博義 and 野田, 哲史 and 奥貫, 裕美 and 大脇, 成広 and 清水, 猛史 and 森田, 真也 and KOIDE, Hiroyoshi and NODA, Satoshi and OKUNUKI, Yumi and OWAKI, Shigehiro and SHIMIZU, Takeshi and TERADA, Tomohiro and MORITA, Shin-ya},
 issue = {5},
 journal = {In Vivo},
 month = {Sep},
 note = {pdf, Background/Aim:
Concurrent chemoradiotherapy with high-dose cisplatin (CDDP-RT) is the standard therapy for advanced head and neck cancer; however, due to CDDP-induced renal impairment, dose reduction or discontinuation is frequently required. Therefore, the identification of risk factors for renal impairment is of importance to improve the efficacy and safety of CDDP-RT., Patients and Methods: 
We retrospectively investigated risk factors for renal impairment in advanced head and neck cancer patients receiving CDDP-RT. Renal impairment was defined as a >25% decrease from baseline in estimated glomerular filtration rate within 14 days after CDDP administration in the first cycle., Results:
Of the 82 patients analyzed in this study, 21 (26%) patients developed renal impairment. Multivariate logistic regression analysis showed that concomitant use of a calcium channel blocker or lower hemoglobin levels significantly contributed to the increased risk of CDDP-induced renal impairment (odds ratio=3.60, 95% confidence interval=1.04-12.40; odds ratio=0.71, 95% confidence interval=0.50-0.99, respectively), while concomitant use of proton pump inhibitors was a factor associated with a decreased risk of CDDP-induced renal impairment (odds ratio=0.20, 95% confidence interval=0.04-0.86)., Conclusion:
Renal function of patients receiving calcium channel blocker or patients with lower hemoglobin levels should be monitored cautiously when receiving CDDP-RT., Journal Article},
 pages = {2465--2472},
 title = {Analysis of Risk Factors for High-dose Cisplatin-induced Renal Impairment in Head and Neck Cancer Patients},
 volume = {36},
 year = {2022}
}